Aravive Inc

-0.56 (-18.12%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)43.45M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.51 Million
Adjusted EPS-$0.60
See more estimates
10-Day MA$3.20
50-Day MA$3.65
200-Day MA$4.85
See more pivots

Aravive Inc Stock, NASDAQ:ARAV

River Oaks Tower, 3730 Kirby Drive, Houston, Texas 77098
United States of America
Phone: +1.936.355.1910
Number of Employees: 17


Aravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.